Kelda M. Gardner

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms

Anna B. Halpern, Megan Othus, Emily M. Huebner et al. · Leukemia · 2018 · 49 citations · Full text

Phase 1/2, Hematological Malignancy, Oncology +8

Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome

Jennifer Vaughn, Megan Othus, Morgan A. Powell et al. · JAMA Oncology · 2015 · 47 citations · Full text

Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia.

Roland B. Walter, Lenise Taylor, Kelda M. Gardner et al. · PubMed · 2013 · 42 citations · Full text

Hematological Malignancy, Malignant Blood Disorder, Intensive Induction +15

Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome

F. Linzee Mabrey, Kelda M. Gardner, Kathleen Shannon Dorcy et al. · Blood Advances · 2020 · 26 citations · Full text

G‐CSF <scp>P</scp>riming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm

Pamela S. Becker, Bruno C. Medeiros, Anthony S. Stein et al. · American Journal of Hematology · 2014 · 19 citations · Full text